Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor

Thomas Jefferson University26 enrolled

Overview

This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.

PRIMARY OBJECTIVE: I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s. SECONDARY OBJECTIVE: I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education. EXPLORATORY OBJECTIVE: I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial. OUTLINE: PHASE I: Patients' medical records are reviewed. PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider. After completion of study, patients are followed up periodically.

Study Type

INTERVENTIONAL

Allocation

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Malignant Solid Neoplasm

Interventions

Medical Chart ReviewOTHER

Review of medical chart

Educational InterventionOTHER

Receive pharmacist-led education

Survey AdministrationOTHER

Ancillary studies

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Solid tumor diagnosis * Starting day 1 of new antineoplastic infusion * English speaking (and/or English-speaking primary caregiver/proxy) Exclusion Criteria: * Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition * Severe cognitive impairment including dementia with inability to consent to the study

Locations (1)

Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Number of medical related problem (MRP)s identified by the pharmacist through retrospective chart reviews (Phase I)

MRPs will be assigned to a specific category and the total number of MRPs in each category will be recorded. Categories include but are not limited to: incorrect dose, therapeutic duplication, drug not indicated, drug interaction, monitoring recommendation, drug allergy, or potential for adverse event.

Time frame: Up to 1 year

Percent of MRPs corrected as a result of the clinical oncology pharmacist services (Phase II)

In phase 2 (prospective) MRPs will also be recorded and categorized, but in addition the outcomes relating to each MRP pharmacist intervention will be recorded. MRPs found by the pharmacist will be communicated to the patient's oncologist or primary care provider, and the pharmacist will follow-up to see if changes were made.

Time frame: Up to 1 year

Secondary Outcomes

Patient and provider satisfaction with the pharmacist-led education

The survey results will help determine the need for a clinical oncology pharmacist in the outpatient infusion center. Satisfaction will be assessed using a Likert-scale survey. Scale ranges from 1 (strongly disagree) to 5 (strongly agree).

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.